GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Purchase Of Investment

Aurinia Pharmaceuticals (FRA:IKAP) Purchase Of Investment : €-477.7 Mil (TTM As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Purchase Of Investment?

Aurinia Pharmaceuticals's purchase of investment for the three months ended in Mar. 2025 was €-85.1 Mil. It means Aurinia Pharmaceuticals spent €85.1 Mil on purchasing investments. Aurinia Pharmaceuticals's purchase of investment for the trailing twelve months (TTM) ended in Mar. 2025 was €-477.7 Mil.

Compared with last quarter (€-80.9 Mil in Dec. 2024 ), Aurinia Pharmaceuticals spent more money on purchasing investments in Mar. 2025 (€-85.1 Mil).

Aurinia Pharmaceuticals Purchase Of Investment Historical Data

The historical data trend for Aurinia Pharmaceuticals's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Purchase Of Investment Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only -166.83 -388.48 -494.65 -480.05 -521.27

Aurinia Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -111.56 -182.89 -128.86 -80.88 -85.09

Aurinia Pharmaceuticals Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-477.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Purchase Of Investment
Comparable Companies
VRDN INVA SNDX IOVA NVAX ADPT WVE LQDA MDXG ETNB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AUPH:USA
Address
14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Website
https://www.auriniapharma.com
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Headlines

No Headlines